NBS Present at Multiple Conferences in November NEW

New Post Public Reply Private Reply Replies (0) Message Board

Nov 2, 2012 at 9:42 AM

[b]NBS >> Present at Multiple Conferences in November[/b]

NEW YORK, Oct. 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in November.

American Heart Association – Scientific Sessions 2012

Date: November 6, 2012, 11:00 AM PST
Venue: Los Angeles Convention Center, Los Angeles, CA
Session Title: Cardiovascular Regeneration: From Bench to Clinic
Presenter: Jonathan Sackner-Bernstein, M.D., FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem will present an abstract titled "Predictors of Response to Intracoronary Delivery of CD34+CXCR4+ Enriched Bone Marrow Derived Stem Cells (AMR-001) Early After STEMI"
2012 ISPE Annual Meeting: Global GMP Solutions through Innovation and Transformation

Date: November 12, 2012, 3:30 PM PST
Venue: Marriott Marquis, San Francisco, CA
Presenter: Sanjin Zvonic, Ph.D., Director of Technology and Business Development of PCT, will speak on "Immunotherapies and Tissue Culture Manufacturing Technologies" within the Biotechnology Executive Series Session
Lazard Capital Markets 9th Annual Healthcare Conference

Date: November 14, 2012, 10:00 AM EST
Venue: The Pierre Hotel, New York, NY
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
New York Society of Security Analysts' 16th Annual "Investing in Life Sciences" Conference

Date: November 29, 2012, 11:15 AM EST
Venue: NYSSA Conference Center, New York, NY
Presenters: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shanghai Hosts 20th Global Entrepreneurship Week

Shanghai: A Hacker's Paradise of Innovation? The heart of financial ambition beats loud and clear in Shanghai this time of year. November 10 to 14, 2026, promises to be a spectacle of entrepreneurial valor as the city hosts the 20th Global Entrepreneurship Week China. This isn't just some run-of-the-mill networking shindig; we're talking about over 50 dazzling events,...

EBONY Celebrates Cultural Icons at 2026 Power 100 Event

Dazzling Night in Los Angeles Honors Black Excellence Step aside Oscars, last night was about powerful celebrations. EBONY threw one hell of a party with its Power 100 event at the Hollywood Palladium. This gathering wasn't just an awards ceremony—it was an explosion of culture, rhythm, and nods to a legacy that’s made waves for over 80 years. Now, what makes this...

Eagle Bank Club Breathing New Life Into Historic Site

Preserving History with Contemporary Flair Sometimes, a building is more than just bricks and mortar, it's the heart of a community's memories. Come spring 2027, Eagle Bank Club is set to throw open its doors, reviving the century-old tradition of gathering in a place that's been etched into the town's identity. Scott Slater and Todd Ketlinski aren't just opening another...

NYSE Salutes Veterans and Shares Market Insights

Honoring Veterans at the NYSE It's not every day you see the hustle and bustle of the NYSE pause for a moment of reflection, but Veterans Day is one of those rare occasions. Before traders dive into the chaos of buying and selling, there's a solemn recognition of those who've soldiered on for our freedoms—a refreshing pause, if you ask me. As Brigadier General Matthew...

Asphalt Additives Market Set for $7.07B Boom by 2031

Asphalt Additives: A Lucrative Growth Path Let me tell you, the asphalt additives market isn't just sticking to the roads; it's rolling out real potential. Heading for a $7.07B finish line by 2031 with a steady pace of 7.3% CAGR, it's a road worth staking your claims on. The underlying story? It's more than just laying tar. Pavement to Profit: Key Drivers The asphalt...

Military Friendly Employers of 2027 Show Strategic Trends

Breaking Down Employer Recognition Well, if you're yearning to see which companies have the savvy to back the troops, the 2027 Military Friendly® Employers list gives us that inside scoop. Rolling out for its 24th annual iteration, 282 employers got the pat on the back this time on www.militaryfriendly.com, and let me say, some familiar names made the grade, but it's the...

Flex LNG's Q3 2026: Steering Through Market Dynamics

Earnings Snapshot: Navigating Through a Challenging Quarter Ah, the quarterly earnings lottery. From the Bermuda docks, Flex LNG has thrown its hat in the ring for Q3 2026, with the game called at $97.4 million in vessel operating revenues. That's a cool $9.4 million shy of last quarter's performance. CEO Marius Foss and his crew are feeling the pressure of narrowing...

Regen™ Yarn Takes Stage in Charity Race Events

Running for Charity, Clothed in Sustainability In the bustling streets of Seoul, they say charity begins at home, but it's picking up pace on the streets too. Just last week, runners in the Save Race 2026 charity event found themselves not just racing for a cause but wearing one too. Hyosung TNC, renowned for pushing eco-friendly textiles, stepped up with their recycled...

PC Richard & Son Offers Big Black Friday Savings

Holiday Prep Kicks Into High Gear As November ticks on, folks are diving headfirst into the frenzy of holiday planning and spending. What better time for a salvo of sales from P.C. Richard & Son? The appliance stalwart is throwing down the gauntlet with hefty discounts and some intriguing offers on TVs, mattresses, and more. With Black Friday looming, the savvy shopper...

Lawyers Juggle AI's Promise and Perils in 2026

AI's Growing Pains in the Legal Arena Looks like the legal eagles are getting a run for their money with AI entering the courtroom. Bloomberg Law's 2026 AI in Practice report dives deep into this legal labyrinth. You got attorneys leaning on AI to keep the gears turning, but they're also clutching their pearls over potential pitfalls. Trust Issues: Humans vs. Machines The...